Nature Biomedical Engineering | Novel Strategy for Tumor Immunotherapy Using PD-L1 and CTLA-4 Bispecific Nanobodies

This study provides a completely new perspective for developing more effective immune checkpoint intervention strategies, particularly inspiring experimental designs targeting pleiotropic immune regulation within the tumor microenvironment. By recruiting endogenous polyclonal antibodies to enhance Fc function, it offers a promising solution to overcome the current low response rates associated with PD-L1-targeted therapies.

 

Literature Overview

The article titled 'Nanobody-based bi-specific antibody engagers targeting CTLA-4 or PD-L1 for cancer immunotherapy,' published in Nature Biomedical Engineering, systematically explores an innovative strategy of using nanobodies to construct bispecific antibody engagers targeting CTLA-4 or PD-L1 to enhance anti-tumor immune responses. The research team designed nanobody fusion proteins incorporating the VHHkappa domain, capable of specifically binding tumor cell surface antigens and recruiting host endogenous polyclonal immunoglobulins, thereby broadly activating Fc effector functions across multiple Ig subtypes. This approach overcomes the limitations of traditional monoclonal antibodies that rely solely on a single IgG subtype’s Fc function, significantly improving anti-tumor efficacy—particularly demonstrating superior activity over conventional antibodies in CTLA-4-targeted therapy.

Background Knowledge

Although significant progress has been made in cancer immunotherapy, only a subset of patients exhibit durable responses to CTLA-4 or PD-L1 blockade therapies. The core challenges lie in the immunosuppressive tumor microenvironment and the limited effector functions of therapeutic antibodies. Most existing immune checkpoint inhibitors are IgG-class monoclonal antibodies, whose Fc regions are often engineered to reduce toxicity, inadvertently weakening critical effector mechanisms such as ADCC and ADCP. Additionally, while PD-L1 is highly expressed on various tumor cells and myeloid cells, the efficacy of targeting it with monoclonal antibodies is limited by their dependence on T-cell reactivation, making it difficult to effectively eliminate immunosuppressive cells. Therefore, enhancing antibody-dependent immune cell clearance—especially the depletion of regulatory T cells (Tregs) or tumor-associated macrophages (TAMs)—has become a key to overcoming current therapeutic bottlenecks. This study's innovation lies in utilizing VHHkappa nanobodies to recruit endogenous antibodies of all Ig subtypes, thereby fully activating FcγR-mediated cytotoxicity and enabling more efficient immune cell infiltration and target cell elimination, offering a novel paradigm for next-generation bispecific antibody design.

 

 

Research Methods and Experiments

The study employed MC38 colon cancer and B16-F10 melanoma mouse models to construct nanobody-VHHkappa fusion proteins targeting CTLA-4 (H11) or PD-L1 (A12). These bispecific VHH-VHHkappa fusion proteins were efficiently produced using an E. coli expression system, and drug conjugation was achieved via sortase-mediated transpeptidation reactions. The authors verified the high-affinity binding of the fusion proteins to target antigens and polyclonal Ig using ELISA, SPR, and flow cytometry. In vivo, the proteins were administered via tail vein injection to assess tumor growth inhibition and survival rates, with immune cell subset dynamics in the tumor microenvironment analyzed using immunohistochemistry and multicolor flow cytometry. Additionally, PD-L1 knockout cell lines were generated using CRISPR/Cas9 to confirm target dependency.

Key Conclusions and Perspectives

• The H11-VHHkappa fusion protein targeting CTLA-4 significantly outperformed the conventional monoclonal antibody 9H10 in the MC38 model, primarily through FcγR-dependent ADCC mechanisms that deplete intratumoral regulatory T cells (Tregs), thereby enhancing anti-tumor immune responses. This finding suggests that future development should prioritize CTLA-4-targeting agents capable of efficiently mediating Treg depletion.
• Although the A12-VHHkappa fusion protein targeting PD-L1 showed improved efficacy over the traditional monoclonal antibody 10F.9G2, its therapeutic effect was limited and dependent on PD-L1 expression by tumor cells rather than myeloid cells. This highlights the importance of tumor cell-autonomous immune escape in current PD-L1 therapies and suggests the need for combination strategies to enhance clearance of suppressive cells such as TAMs.
• Conjugation of cytotoxic drugs like maytansine (DM4) or STING agonists significantly enhanced the anti-tumor activity of A12-VHHkappa, achieving tumor control even in the B16-F10 model. This strategy provides a new avenue for enhancing the direct killing capacity of PD-L1-targeted therapeutics, supporting the development of antibody-drug or antibody-immune agonist conjugates.
• The half-life of the fusion proteins was significantly prolonged due to binding with circulating Ig, without triggering systemic toxicity or autoimmune reactions. This indicates that the VHHkappa-mediated Ig recruitment strategy offers favorable safety and pharmacokinetic advantages, making it suitable for further clinical translation.

Research Significance and Prospects

This study presents a novel platform for drug development—using nanobody-based bispecific designs to combine targeting capability with endogenous antibody effector functions, avoiding the complexity of engineering exogenous Fc regions. Particularly for targets like PD-L1, where conventional monoclonal antibodies struggle to fully block immunosuppression, this strategy—by directly killing PD-L1+ cells—may more completely relieve immune inhibition. In clinical monitoring, changes in Treg proportions, neutrophil infiltration, and IFN-β levels before and after treatment could be explored as predictive biomarkers of therapeutic efficacy.

 

 

Conclusion

This study innovatively designed VHHkappa-based bispecific nanobody engagers, significantly enhancing CTLA-4 and PD-L1 targeted therapies. Its core value lies in leveraging host endogenous polyclonal antibodies to fully activate Fc effector functions across multiple Ig subtypes, enabling efficient depletion of regulatory T cells and tumor-associated macrophages, thereby reshaping the tumor immune microenvironment. This strategy not only overcomes the limitations of traditional monoclonal antibodies in effector function but also enhances direct cytotoxicity through drug conjugation, offering new therapeutic avenues for refractory tumors. From bench to bedside, this platform demonstrates strong developability and applicability to various tumor antigen targets, potentially becoming a cornerstone technology for next-generation immunotherapies—particularly showing great promise in improving response rates for PD-L1-targeted treatments. Future research should focus on developing humanized versions and validating them in humanized mouse models to accelerate clinical translation.

 

Xin Liu, Camille Le Gall, Ryan K Alexander, Thomas Balligand, and Hidde L Ploegh. Nanobody-based bi-specific antibody engagers targeting CTLA-4 or PD-L1 for cancer immunotherapy. Nature biomedical engineering.